New approaches to cancer clinical trials aim to support rapid, cost-effective studies that effectively answer clinical questions to improve patient care.
Our Registry Trials program combines conventional trial methodology with registry systems to produce real-world clinical evidence. The approach integrates the high internal validity (elimination of bias) of randomised clinical trials with the high external validity (applicable to a clinical setting) associated with enrolling real-world patients.
Patient accessible trials, producing cost-efficient, rapid outcomes
Randomised-controlled trials (RCT) are a clinical trial method that provides high-level scientific evidence and is the gold standard for comparing care approaches or treatment options. RCTs provide rigorous evidence to support clinician decision-making. However, RCTs commonly have narrow eligibility criteria, limiting patient recruitment and external validity, as well as substantial per patient costs.
In contrast, registry-based randomised controlled trials, or registry trials, operate with broad eligibility criteria, enabling trial access to a large group of participants who represent real-world patients. Data collection is achieved via the registries during routine care practices, delivering valuable infrastructure for collecting baseline and outcome treatment data.
Combining patient access with comparable randomised treatment researchers can answer simple, pragmatic questions, such as treatment duration, strategies or combinations, at a far lower cost than conventional randomised trials.
Proof-of-concept evaluation in an oncology setting
The registry trials approach has demonstrated excellent results in cardiovascular trials, generating high impact publications that have changed standard of care treatments. Our program aims to, for the first time, assess this approach in an oncology setting.
Registry trials will be conducted on specific tumour streams including both common and rare cancer types. Data will be collected in routine care processes from a range of health services, enabling recruitment of a large patient group. An in-depth methodology and design analysis will be undertaken to provide a critical evaluation of the registry trials approach and to identify success factors.
Cost-effective method; increasing investigator experience
Hypothetically, the registry trials approach is a suitable, cost-effective way to pursue clinical oncology questions, while maintaining trial rigour.
Registry trials can be conducted within usual care and are a means of introducing early career clinicians to initiating and leading clinical trials; increasing investigator experience.
VCCC alliance partners provide a critical mass of proven clinical trial facilities and infrastructure. Partner clinical sites, as well as other health services, will provide resources to promote the trials, support recruitment and deliver data management and analysis.
A research fellow from the Evaluation and Implementation Science Unit, Centre for Health Policy, University of Melbourne will conduct the evaluation. Meticulous analysis and evaluation of oncology registry trials will provide beneficial insights for local and international health services as well has community health outcomes.
Further information and contacts
A comparison of conventional clinical trials and registry-based randomised controlled trials in multidisciplinary cancer care:
Foroughi S, Wong HL, Gately L, Lee M, Simons K, Tie J, Burgess AW, Gibbs P. Re-inventing the randomized controlled trial in medical oncology: The registry-based trial. Asia Pac J Clin Oncol. 2018 Jun 26. doi: 10.1111/ajco.12992.
For further information about the Registry Trials program email Evelien Rosens, Program Manager or phone 03 8559 8583.